ORKA-001 EVERLAST-A 16-week data showed 63.5% PASI 100 rate and a favorable tolerability profile, with longer-term data expected in 2H 2026 ORCA-SURGE Phase 2 trial of ORKA-002 in psoriasis initiated ...
Our post‑spring rankings stack up the quarterbacks most capable of defining college football this upcoming season.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results